View Older Stories View More Recent Stories

Dec 23, 2019 08:05AM U.S. FDA Approves Eisai's DAYVIGO™ (lemborexant) for the Treatment of Insomnia in Adult Patients
Dec 10, 2019 08:35AM Eisai Presents New Analyses of Potential Blood-Based Alzheimer's Diagnostic Test and Lemborexant as Potential Sleep-Wake Disorder Therapy
Dec 10, 2019 08:08AM Eisai to Present New Data on HALAVEN® (eribulin mesylate) Injection at 42nd Annual San Antonio Breast Cancer Symposium
Dec 9, 2019 10:06AM Lower Hospitalization Rates Seen Among Epilepsy Patients Treated with FYCOMPA® and Select Anti-Epileptic Drug (AED) Combinations
Dec 9, 2019 08:06AM Eisai Presents New Seizure Freedom and Adherence Data Related to Anti-Epileptic Drug FYCOMPA® at the 2019 American Epilepsy Society Annual Meeting
Dec 5, 2019 08:35AM Beneath the Breast Campaign from Eisai and METAvivor Supports Relationship Challenges Commonly Faced by People Living with Metastatic Breast Cancer and their Loved Ones
Dec 2, 2019 10:18AM Eisai and Biogen's Joint Investigational Asset BAN2401 Data to be Presented at Clinical Trials on Alzheimer's Disease Conference
Nov 25, 2019 08:06AM Eisai to Present Convulsive Seizure Freedom Data Evaluating FYCOMPA® in Newly Diagnosed Partial Onset Patients at Upcoming American Epilepsy Society Annual Meeting
Nov 12, 2019 08:35AM Eisai Launches First Amazon Alexa Skill Designed to Engage with Those Impacted by Lennox-Gastaut Syndrome - a Rare and Severe Form of Childhood-Onset Epilepsy
Sep 27, 2019 01:24PM Three New Analyses of Data Expand Understanding of the Potential Role for Investigational Agent Lemborexant in Insomnia and Irregular Sleep-Wake Rhythm Disorder
Sep 24, 2019 08:37AM New Findings Presented at World Sleep Congress Reveal Perceptions of "Having a Good Day" Determined by the Previous Night's Sleep
Sep 24, 2019 08:08AM Eisai Announces Data Presentations on KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and HALAVEN® (eribulin) at ESMO 2019
Sep 19, 2019 12:35PM Eisai to Present New 12-month Safety & Effectiveness Data from Phase 3 Lemborexant SUNRISE 2 Study and New Patient and Cohabitant Insights about Insomnia and Toll on Next-Day Functioning at World
Sep 13, 2019 08:01AM Eisai And Biogen (BIIB) to Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
Sep 13, 2019 08:00AM Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
Aug 26, 2019 07:55AM Priya Chaturvedi, Ph.D., Appointed Vice President of Global Clinical Quality Assurance at Eisai Inc.
Jul 22, 2019 10:37PM Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Breakthrough Therapy Designation from FDA
Jun 25, 2019 08:00AM Eisai Presents Data To Assess Seizure Freedom With FYCOMPA® Monotherapy In Newly Diagnosed Or Untreated Patients With Partial Onset Seizures
Jun 13, 2019 08:05AM Eisai To Present FYCOMPA® Seizure FREEDOM Data In New Onset Patients And Pediatric Data At The 33rd International Epilepsy Congress
Jun 4, 2019 08:00AM Patrick Coyle Appointed Vice President and Chief Financial Officer of Eisai Inc.
May 16, 2019 12:45PM Eisai Announces Data Presentations on Oncology Pipeline, including LENVIMA® (lenvatinib) plus KEYTRUDA® (pembrolizumab) Investigational Combination Therapy at ASCO 2019
May 10, 2019 08:40AM Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer's Disease
May 9, 2019 01:17PM Lower Hospitalization Rates In Epilepsy Patients Treated With Adjunctive FYCOMPA® (perampanel) CIII
Mar 29, 2019 08:08AM Eisai Announces Presentations of Latest Research on Oncology Pipeline at the 110th American Association for Cancer Research (AACR) Annual Meeting
Feb 25, 2019 08:01AM FDA Accepts Eisai's Supplemental New Drug Application (sNDA) to Update the Labeling for Anti-Obesity Agent BELVIQ® (lorcaserin HCl)
Feb 20, 2019 11:50PM AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa
Feb 19, 2019 10:05AM Eisai and Empatica Enter an Agreement to Co-Promote the Embrace2 Device for People Living With Epilepsy in the U.S.
Feb 11, 2019 08:35AM METAvivor and Presenting Sponsor Eisai Inc. Join Forces with AnaOno Intimates to Bring to Life the #ThisIsMBC Elements Campaign through Fashion
Dec 5, 2018 07:24PM Eisai and UCL Commence Preparations for Phase I Clinical Studies in Alzheimer's Disease for Novel Anti-Tau Antibody E2814 Discovered Through Joint Research
Nov 28, 2018 08:35AM Eisai and METAvivor Team Up to Launch Elements as the Latest #ThisIsMBC Initiative at the 2018 San Antonio Breast Cancer Symposium
Oct 28, 2018 07:45PM Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at CTAD
Oct 25, 2018 06:03PM Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimer's Disease
Oct 24, 2018 10:00AM Eisai and Oklahoma Health Care Authority Enter Value-Based Agreement for FYCOMPA
Oct 22, 2018 03:34AM Eisai and MSD Japan Commence Collaboration on Commercialization Activities for LENVIMA (Lenvatinib) in Japan
Oct 17, 2018 07:30PM Eisai To Present Latest Data On Alzheimer's Disease / Dementia Pipeline At The 11th Clinical Trials On Alzheimer's Disease (CTAD) Conference
Oct 16, 2018 08:08AM Eisai To Present New Research On Human Genetics And Drug Discovery At ASHG Conference 2018
Oct 4, 2018 07:30AM Eisai Announces New Data on the Effect of Anti-Obesity Agent BELVIQ® (lorcaserin HCl) on Prevention and Remission of Type 2 Diabetes Presented at the European Association for the Study of Diabetes (E
Sep 28, 2018 02:54PM Eisai Announces FDA Approval Of FYCOMPA® in Pediatric Patients As Young As 4 Years Old For The Treatment Of Partial-Onset Seizures
Aug 27, 2018 11:56AM Eisai Announces Long-Term Cardiovascular Outcomes Data for Anti-Obesity Agent BELVIQ® Presented at the European Society of Cardiology and Published in the New England Journal of Medicine
Aug 17, 2018 08:00AM Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Aug 16, 2018 04:11PM Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Jul 30, 2018 09:27PM Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA
Jul 18, 2018 08:00AM Eisai To Present Latest Data On Alzheimer's Disease / Dementia Pipeline At Alzheimer's Association International Conference 2018
Jul 17, 2018 09:00AM Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI 61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ®
Jul 9, 2018 10:20PM Eisai Announces Acceptance of BAN2401 Phase II Results for Oral Presentation at the 2018 Alzheimer's Association International Conference (AAIC)
Jun 12, 2018 04:30PM Eisai Inc. to Launch Center for Genetics Guided Dementia Discovery in Cambridge, Massachusetts
Jun 11, 2018 02:00PM Lihua Yu, Ph.D., Appointed President & Chief Data Sciences Officer, H3 Biomedicine
Jun 5, 2018 01:58PM Eisai, Biogen (BIIB) Report Phase II Study Of Elenbecestat Demonstrated Safety And Tolerability In MCI And Mild To Moderate AD At 18-Months
Jun 5, 2018 01:55PM Phase II Clinical Study Of Elenbecestat Demonstrates Safety And Tolerability In MCI And Mild To Moderate Alzheimer's Disease At 18-Months
Jun 3, 2018 06:00PM Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigational Studies of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy in Four Different Tumor Types
View More Recent Stories View Older Stories